NCT05281614View on ClinicalTrials.gov

Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

Etanercept

Etanercept is a fully humanized monoclonal antibody that targets TNFα.

DRUG

Vedolizumab

Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.

Trial Locations (2)

92037

University of California San Diego, La Jolla

98102

Benaroya Research Institute, Seattle

Sponsors
All Listed Sponsors
collaborator

University of California, San Diego

OTHER

lead

Benaroya Research Institute

OTHER